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Identity 
Alias: Clear cell sarcoma of soft parts. 
Classification 
This tumour, initially described by Enzinger as "clear 
cell sarcoma of tendons and aponeuroses", is of 
uncertain origin, but its immunohistochemical profile 
shows its melanocytic nature; however it has no genetic 
relationship with the cutaneous malignant melanoma. 
Clinics and pathology 
Embryonic origin 
Being of melanocytic origin, this tumour should be 




It is a very rare tumour representing a minority of all 
soft tissue sarcomas. 
Clinics 
The malignant melanoma of soft parts (MMSP) 
preferentially occurs in young adults, between ages of 
20 and 40 years; the tumour develops mainly in the 
extremities, especially the legs (foot, knee, heel, ankle); 
it is usually deeply seated, and often bound to tendons 
and aponeuroses. 
Pathology 
The tumours show compact nests and strands of round 
or fusiform cells with a clear cytoplasm, separated by 
fibrocollagenous tissue often connected to adjacent  
tendons or aponeuroses; mitotic index is generally low; 
the cells of nearly all cases express S-100 protein and 
the melanoma-associated antigen HMB45. 
Treatment 
The treatment protocols vary greatly according to the 
institutions; however, the melanoma of soft parts is a 
highly malignant tumour which requires surgical 
excision combined with radiotherapy and/or 
chemotherapy. 
Evolution 
Many patients develop recurrences and regional and 
distant metastases, in lymph nodes, lung, and bones; in 
the series of Enzinger, the average time between 
diagnosis and recurrence was 2.6 years, between 
diagnosis and metastasis, 3.5 years. 
Prognosis 
The prognosis is poor; in the series of 115 patients 
studied by Enzinger, 46% had died; of the 62 living 
patients, 21 experienced one or more recurrences, and 7 
had a metastatic disease. 
Cytogenetics 
Cytogenetics Morphological 
This tumour is characterised by the presence of a 
chromosome translocation t(12;22)(q13;q12), which 
involves genes ATF-1, on chromosome 12, and EWS, 
on chromosome 22. 
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The chimaeric protein is composed of the N-terminal 
domain of EWS linked to the bZIP domain of ATF-1. 
Oncogenesis 
Binds to ATF sites present in cAMP-responsive 
promoters via the ATF1 bZIP domain and activates 
transcription constitutively, dependent on the activation 
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